Profound management will host a conference call at
Third Quarter 2023 Results Conference Call Details
Date:
Time:
Live Call Registration: https://register.vevent.com/register/BIe4cb03c9ce9e491187ff191c8a874810
The call will also be broadcast live and archived on the Company's website at www.profoundmedical.com under 'Webcasts' in the Investors section.
About
Profound is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue.
Profound is commercializing TULSA-PRO, a technology that combines real-time MRI, robotically-driven transurethral ultrasound and closed-loop temperature feedback control. TULSA-PRO is designed to provide customizable and predictable radiation-free ablation of a surgeon-defined prostate volume while actively protecting the urethra and rectum to help preserve the patient's natural functional abilities. TULSA-PRO has the potential to be a flexible technology in customizable prostate ablation, including intermediate stage cancer, localized radio-recurrent cancer, retention and hematuria palliation in locally advanced prostate cancer, and the transition zone in large volume benign prostatic hyperplasia ('BPH'). TULSA-PRO is CE marked,
Profound is also commercializing Sonalleve, an innovative therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases. Sonalleve has also been approved by the
Contact:
Email: skilmer@profoundmedical.com
Tel: 647.872.4849
(C) 2023 Electronic News Publishing, source